The relationship of hepatits b core antibody positivity with demographic and laboratory parameters in hemodialysis patients


Bozaci I., TOSUN S.

Haseki Tip Bulteni, cilt.59, sa.3, ss.255-260, 2021 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/haseki.galenos.2021.6883
  • Dergi Adı: Haseki Tip Bulteni
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.255-260
  • Anahtar Kelimeler: Hepatitis B virus, hepatitis B antibodies, hepatitis B core antigens, hemodialysis
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aim: The presence of hepatitis B core antibody (HBcAb ) is an indication of exposure to hepatitis B virus infection. We aimed to investigate the rates of positive HBcAb and its’ association with demographical and laboratory parameters among patients undergoing hemodialysis. Methods: Patients were divided into two groups such as HBcAb positive and HBcAb negative. This study was conducted at a training and research hospital over 3 months period between October and December 2020. Demographical data and laboratory results were recruited from most recent medical records. Results: A sum of 237 patients on hemodialysis were enrolled in the study. Fifty nine patients (25%) were HBcAb positive and 178 patients (75%) were HBcAb negative. Statistically significant difference was found between groups in terms of anti-HBs positivity (96.6% vs 79.2%; p=0.002), diabetes mellitus (DM) prevalence (32% vs 19%; p=0.036) and white blood cell count (WBC) levels (7.7±2.5 x103/ µL vs 7.1±2.1 x103/µL; p=0.044). In linear regression analysis (variables: age, HBsAb, WBC and DM) HBcAb was found independently associated with age (t: 3.139; p=0.002), HBsAb (t: 3.998; p<0.001), WBC (t: 2.166; p=0.031) and DM (t: 2.749; p=0.006). Conclusion: We found high rates of positive HBcAb. Positive HBcAb should be taken into account in immune-compromised patients such as dialysis patients.